Avalo Therapeutics, Inc. · NASDAQ:AVTX

Doyle Mittie sold 1,450 Avalo Therapeutics, Inc. shares (Form 4)

Traded Jun 23, 2026 · Filed Jun 25, 2026

On Jun 23, 2026, Doyle Mittie (Chief Medical Officer) sold 1,450 Avalo Therapeutics, Inc. shares at US$18.00 for US$26,100 under a trading plan, leaving 51,776 shares. Filed Jun 25, 2026 (Form 4).

Sold
1,450 shares
Price
US$18.00
Value
US$26,100
Holding after
51,776 shares
Trading plan
Yes (Made under a plan set in advance)
Role
Chief Medical Officer

The filing in full

DateSecurityTransactionSharesPriceHolding afterOwnership
Jun 23, 2026Common StockOption exercise1,450US$8.0453,226Direct
Jun 23, 2026Common StockSale1,450US$18.0051,776Direct

Source

View original at SEC

Related